The pharmaceutical giant raised its full-year guidance after third-quarter revenue and core earnings per share topped ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

Shares of AstraZeneca PLC AZN advanced 1.46% to £102.92 Thursday, on what proved to be an all-around positive trading session ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating yesterday. Andrew Berens gave his rating based on several factors, including AstraZeneca’s ...

AstraZeneca (GB:AZN) has released an update. AstraZeneca’s Senior Independent Non-Executive Director, Philip Broadley, has made a notable ...

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall ...

The data showed that Koselugo met its primary endpoint, demonstrating a statistically significant and clinically meaningful ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...